Announced Tue, 27 Oct, 2026 · 17:14 IST
Mankind Pharma outlines FY30 growth, debt reduction and ACTx plans
Analyst Day Multiyear TargetsCfo Debt Reduction RoadmapMgmt Guided Margin ImprovementInvestor Communications View source PDFExplain this filing
MANKIND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction
Awaiting price reaction for this filing.
AI summary
Mankind Pharma said FY26 revenue reached ₹14,278 crore, with 18.1% growth over FY21-FY26. It targets a chronic sales share of about 50% by FY30 from 39% in FY26, wants acquisition debt repaid by 2028, and expects better gross margins and operating leverage. The company has 32 plants and plans five advanced CAR-T programs.
Likely market impact
FY30 growth and 2028 debt goals support long-term growth and cash flow, but the ACTx deal adds treatment risk and near-term funding needs.